Turnover: 3.6 billion EUR (2022)
Country: France
BioMerieux is a French company founded in 1897 by Michel Merieux, a pupil of Louis Pasteur, who first developed anti-tetanus serums.
The group employs over 11,000 people worldwide.
BioMérieux is a major player in the in vitro diagnostics market.
The fruit of a family commitment handed down from generation to generation, the company is present in 160 countries, including 43 with a direct presence. Bio Merieux also has 19 industrial sites and 20 R&D centers.
News
BioMérieux boosts capacity at its French plants 27/06/2023
- BioMérieux investment plan: 300 million euros over five years
- BioMérieux sales: 3.6 billion euros
- BioMérieux workforce: 13,800 people
- Test kit market growth: 10% per year
- Volume of kits assembled by BioMérieux: 130 to 140 million per year
bioMérieux: end of Covid brings testing champion back down to earth 09/03/2023
- Family-owned group with 13,000 employees
- Annual profit reduced from €601 in 2021 to €452 million in 2022, despite sales increasing by 6.3% to €3.6 billion due to the acquisition of US ultra-rapid antibiotic resistance testing company Specific Diagnostics
BioMérieux invests in an ultra-fast antibiotic resistance test. 20/05/2022
- BioMérieux is the world leader in antibiotic resistance testing, with a 40% market share.
- The antibiotic resistance testing market represents 10% of bioMérieux sales.
- Acquisition of California-based Specific Diagnostics
- Specific Diagnostics' test is sufficiently innovative for bioMérieux to have triggered the acquisition of the company.
- The California-based company has 82 employees.
- BioMérieux forecasts sales of $60 million over the next five years,
Financial Data
DUNS: 673620399
Legal Name: BIOMERIEUX SA
Address: , 69280 Marcy-l'Étoile
Number of employees: Entre 2 000 et 4 999 salariés (2020)
Capital: 12 029 370 EUR
Financial Data:
| Year | 2021 | 2020 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|
| Turnover | 1 456 700 000 | 1 301 100 000 | 1 137 600 000 | 1 039 000 000 | 962 000 000 |
| Gross margin (€) | 921 000 000 | 1 318 300 000 | 1 564 600 000 | -12 700 000 | -5 400 000 |
| EBITDA (€) | 151 000 000 | 100 800 000 | 1 918 000 000 | 46 300 000 | 54 600 000 |
| Operating profit (€) | 73 500 000 | 13 000 000 | 69 700 000 | 46 300 000 | 54 600 000 |
| Net profit (€) | 205 000 000 | 23 800 000 | 109 200 000 | 69 000 000 | 75 700 000 |
| Turnover growth rate (%) | 12 | 3,4 | 9,5 | 8 | - |
| Ebitda margin rate (%) | 10,4 | 7,7 | 168,6 | 4,5 | 5,7 |
| Operating margin rate (%) | 5 | 1 | 6,1 | 4,5 | 5,7 |
| Working Capital (turnover days) | 62,2 | 76,6 | 13,8 | 7,5 | 13 |
| Working Capital requirements (turnover days) | 109,2 | 109,6 | 51,6 | 47,8 | 56 |
| Net margin (%) | 14,1 | 1,8 | 9,6 | 6,7 | 7,9 |
| Added value / Turnover (%) | 37,8 | 37,8 | 137,5 | 75,1 | 76,6 |
| Wages and social charges (€) | 357 700 000 | 328 000 000 | -288 000 000 | - | - |
| Salaries / Turnover (%) | 24,6 | 25,2 | -25,3 | - | - |
Company Managers:
| Position | First Name | Last Name | Age | |
|---|---|---|---|---|
| Président du conseil d'administration | Alexandre Simon Claude | MERIEUX | 50 | |
| Directeur général | Alexandre Simon Claude | MERIEUX | 50 | |
| Directeur général délégué | Pierre Christian Claude | BOULUD | 52 | |
| Administrateur | Alexandre Simon Claude | MERIEUX | 50 | |
| Administrateur | Jean-Luc | BELINGARD | 76 | |
| Administrateur | Philippe André Alfred | ARCHINARD | 65 | |
| Administrateur | Harold | BOËL | 60 | |
| Administrateur | Marie-Hélène | DASSAULT | 59 | |
| Administrateur | Agnès | POIRIER | 69 | |
| Administrateur | Fanny Gisèle Thérèse | DEBREYNE | 45 | |
| Administrateur | Marie-Paule | KIENY | 69 | |
| Administrateur | Sylvain Emile Antoine | ORENGA | 59 |
Studies mentioning this company
The in vitro diagnostics market - France
Other companies mentioned:
- Roche Groupe
- Diagast
- Abbott Groupe
- Danaher
- Thermo Fisher Diagnostics
- Sebia
- BioMerieux Groupe
- Diagnostica Stago
- Biosynex
- Diagnostic Medical System DMS Groupe
The medical laboratories market - France
Other companies mentioned:
- Inovie
- Biogroup
- Synlab Groupe
- Cerba Healthcare
- Unilabs
- Eurofins Groupe
- Oriade-Noviale
- Eurofins
- BioMerieux Groupe
- Ouest Biologie